Further studies will be required to assess the effects of these CFTR-targeted drugs on restoration of salivation and on AQP5 protein expression and distribution in SG in patients suffering from other physiopathological conditions leading to xerostomia (e.g., SS patients). This evidence concerns the gene AQP5 and xerostomia.